FRA:UR9 (Australia)  
Clinuvel Pharmaceuticals Ltd logo

Clinuvel Pharmaceuticals Ltd

€ 11.96 (+0.08%) Nov 25
P/E:
45.88
P/B:
7.28
Market Cap:
€ 593.86M ($ 621.92M)
Enterprise V:
€ 515.69M ($ 540.06M)
Volume:
807.00
Avg Vol (2M):
1.40K
Also Trade In:
Volume:
807.00
Market Cap €:
593.86M
Market Cap $:
621.92M
PE Ratio:
45.88
Avg Vol (2-Month):
1.40K
Enterprise Value €:
515.69M
Enterprise Value $:
540.06M
PB Ratio:
7.28
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Clinuvel Pharmaceuticals Ltd is an Australia-based biopharmaceutical company. It is engaged in developing drugs for the treatment of genetic and vascular disorders. Its principal compound, SCENESSE is a drug for erythropoietic protoporphyria. Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to harmful UV radiation and at repigmentation of the skin due to several depigmentation disorders. Geographically, it derives a majority of its revenue from Europe and the USA.
Name Current Vs Industry Vs History
Cash-To-Debt 96.74
Equity-to-Asset 0.87
Debt-to-Equity 0.01
Debt-to-EBITDA 0.03
Interest Coverage 15.54
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 31.79
Distress
Grey
Safe
Beneish M-Score -3.37
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 23.08
9-Day RSI 37.66
14-Day RSI 43.5
6-1 Month Momentum % 13.29
12-1 Month Momentum % -39.37

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.24
Quick Ratio 10.1
Cash Ratio 8.85
Days Inventory 94.78
Days Sales Outstanding 77.39
Days Payable 73.64

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 42.91
EPS (TTM) (€) 0.264
Beta 0
Volatility % 51.63
14-Day RSI 43.5
14-Day ATR (€) 0.240473
20-Day SMA (€) 12.3525
12-1 Month Momentum % -39.37
52-Week Range (€) 9.004 - 19
Shares Outstanding (Mil) 49.41

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Clinuvel Pharmaceuticals Ltd Filings

Document Form Filing Date
No Filing Data

Clinuvel Pharmaceuticals Ltd Analysis

Share your research